Key Takeaways

  • Heidelberg Engineering has received FDA clearance for the latest Spectralis Software Version, introducing faster OCTA imaging, expanded multimodal capabilities, and workflow enhancements 
  • The new 250 kHz OCTA scan speed, combined with enhanced TruTrack Active Eye Tracking and SHIFT Technology, delivers the fastest OCTA image acquisition available on Spectralis 

Heidelberg Engineering announced FDA clearance for the latest Spectralis software, which introduces new imaging capabilities designed to enhance workflow efficiency, diagnostic confidence, and patient-centered care.

According to Heidelberg, the software release delivers advances in multimodal retinal imaging, including a new 250 kHz scan speed for Optical Coherence Tomography Angiography (OCTA), enhanced TruTrack Active Eye Tracking, and the introduction of the Green Autofluorescence Module. The new features are designed to expand clinical insight while maintaining the image quality and data consistency of the Spectralis platform.

Faster OCTA Imaging with SHIFT Technology

The latest release of Spectralis with SHIFT Technology introduces a 250 kHz scan speed for OCTA imaging, complementing the platform’s existing 85 kHz and 125 kHz acquisition speeds. Supported by enhanced TruTrack Active Eye Tracking, the new scan speed delivers the fastest OCTA image acquisition available on Spectralis to date, helping accelerate imaging workflows in clinical practice.

The platform’s multi-speed imaging approach allows clinicians to tailor acquisition settings based on individual patient needs and clinical objectives, balancing image detail and acquisition time while supporting efficient patient throughput.

The newly introduced Green Autofluorescence Module enhances visualization of the macula and supports the identification of clinically relevant features, including foveal sparing in patients with macular atrophy. The technology is designed to aid diagnosis, patient selection, and disease monitoring, while compatibility with Heidelberg Engineering’s RegionFinder software enables quantification of atrophy for clinical assessment and longitudinal analysis. Combined with BluePeak blue autofluorescence imaging, the Green Autofluorescence Module provides clinicians with complementary views of retinal structure and metabolic changes, offering a more comprehensive understanding of disease progression.

The software release also includes additional features intended to improve clinical workflow efficiency, patient comfort, and advanced imaging capabilities across the Spectralis platform, according to Heidelberg.

Commercial availability of the FDA-cleared software is planned for the second half of the year.